PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announces the presentation of its results on a new quinoline family acting as HIV integrase inhibitors at the 16th Conference on Retroviruses and Opportunistic Infections (CROI), in Montreal, Canada (February 8 to 11, 2009).
